VIDEO: Unmet need in ACLF presents ‘very large opportunity’ for new technology

In this Healio video exclusive, Dean Hum, PhD, chief scientific officer at Genfit, outlines five ongoing programs in the company’s acute-on-chronic liver failure development pipeline, which recently were presented at The Liver Meeting.

The programs focus on key pathophysiology pathways of ACLF, Hum noted, including systemic inflammation, cell death and gut dysbiosis, among others. Featured in the drug candidate pipeline are liposomal-based technology, an anti-inflammatory and antibacterial agent and an ASK1 inhibitor.

“It’s clear that there’s a huge unmet need in ACLF and, actually, there’s no drug that is approved for the treatment of ACLF patients,” Hum said. “It’s a very large opportunity, which is why at Genfit we have taken upon the challenge to build a pipeline of different technologies to address ACLF. Right now our pipeline has multiple mechanisms of action aimed at the treatment of ACLF patients with one or two organ failures.”

Reference:

• Genfit highlights ACLF development strategy at “ACLF Day” during AASLD The Liver Meeting 2023. https://ir.genfit.com/news-releases/news-release-details/genfit-highlights-aclf-development-strategy-aclf-day-during. Published Nov. 16, 2023. Accessed Dec. 12, 2023.